Skip to content
lifestyle.dietfitnessforall.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NOVO NORDISK INC.
Novo post hoc analysis finds Wegovy® 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026
November 8, 2026
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
November 6, 2026
Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world
October 29, 2026
Novo to present new liver data across Wegovy 2.4 mg and investigational efruxifermin at The Liver Meeting® (AASLD) 2026
October 28, 2026
Novo’s CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting
October 22, 2026
People switching from weight-loss injections to Novo’s Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026
September 30, 2026
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
April 2, 2026